Orexigen soars on CV data that FDA didn't want released
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics soared 32% to close at $7.64 per share on 3 March after the San Diego-based company disclosed a newly issued patent for its weight loss drug Contrave (naltrexone and bupropion) that contained positive interim results from a cardiovascular outcomes trial (CVOT) known as the Light study – data that the US FDA expressly asked Orexigen not to disclose.
You may also be interested in...
Orexigen Begins Slow Climb Up Slippery Slope Of Obesity Drug Sales
Orexigen has a tough climb ahead as it sets out without a US partner to boost sales for its obesity drug Contrave with the goal of profitability by 2019, but it appears that doctors, patients and payers are becoming more open to pharmaceutical treatment.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.